摘要
目的探讨西酞普兰(一泰纳)治疗伴躯体疾病的老年抑郁症临床疗效和安全性。方法将62例伴躯体疾病的老年抑郁症患者随机分两组,每组31例,分别给予西酞普兰和文拉法辛治疗6周。治疗前及治疗2、4、6周分别采用汉密尔顿抑郁量表(HAMD)评定临床疗效,不良反应发生率评定不良反应。结果文拉法辛HAMD减分率在治疗2周时大于西酞普兰,二者HAMD减分率存在显著性差异(P<0.05),二者在4、6周HAMD减分率同期相比无显著性差异(P>0.05)。但治疗6周后与治疗前相比均存在极显著性差异(P<0.01)。不良反应发生率:西酞普兰为11.3%,文拉法辛38.2%,二者有显著性差异(P<0.05)。结论西酞普兰与文拉法辛疗效相当,文拉法辛起效快,但西酞普兰较文拉法辛不良反应更少更轻,尤其适用于伴躯体疾病老年抑郁症的长期维持治疗。
Objective To citalopram and venlafaxine （ venlafaxine ） treatment with somatic disease clinical curative effect and safety of senile depression. Methods 62 patients with somatic diseases in the elderly patients with depression were randomly divided into two groups, 31 cases in each group, were given citalopram and venlafaxine in the treatment of 6 weeks. Treatment before treatment and 2, 4, 6 weeks respectively using the Hamilton Depression Rating Scale （HAMD） assessment of clinical efficacy, adverse reaction rate evaluation of adverse reactions, Results Venlafaxine in the treatment of HAMD reduction rate at 2 weeks than citalopram, both HAMD reduction rate exist significant differences （P〈0.05）, both in 4, 6 weeks in the HAMD reduction rates compared with no significant difference （P〉0.05）. But 6 weeks after treatment compared with before treatment there was a significant difference（P〈0.01）. The incidence of adverse reactions to 11.3%： citalopram, venlafaxine in 38.2%, the difference was significant （P〈0.05）. Conclusion Citalopram and venlafaxine venlafaxine equivalent in efficacy, rapid onset, but citalopram with venlafaxine less adverse reactions and lighter, especially for senile depression with somatic diseases in long-term maintenance treatment.
出处
《中国医药指南》
2012年第21期15-17,共3页
Guide of China Medicine
